TY - JOUR T1 - Global association of obesity and COVID-19 death rates JF - medRxiv DO - 10.1101/2021.03.09.21253222 SP - 2021.03.09.21253222 AU - Mary L. Adams Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/12/2021.03.09.21253222.abstract N2 - Importance COVID-19 was responsible for an enormous global death toll with large variation among countries.Objective To examine the possible impact of obesity on COVID-19 death rates.Design Measure associations between obesity rates in 2016 and COVID-19 deaths/million population through 2/25/2021, across countries.Setting GlobalParticipants 167 countries for which obesity and death data were available, grouped by population size, with multiples of 10 countries in each of 8 groups plus a group including all 57 countries with obesity rates <15%.Outcome and measures Using Excel, COVID-19 deaths/million were regressed on the obesity rate for each country, based on obesity being a key factor in COVID hospitalizations and deaths. Using the least squares formula for the best fit for each model, R2, components of the formula, and the percentage of world population represented, were recorded for each group.Results Obesity rates ranged from 2.1% to 37.9% and death rates ranged from 0.4/million to 1,892/million for groups representing up to 91% of global population. Results for the 8 population groups had R2 from 0.30 to 0.90 with slopes of the fitted line ranging from 27.9-51.0. Countries with obesity rates <15% had consistently low death rates (≤233/million), R2 of 0.003 and slope of the line=1.01.Conclusions For most countries about one-third of the difference in COVID death rates was due to obesity while in countries with obesity <15%, consistently low death rates were not associated with obesity. Reduced obesity rates could potentially have lowered the COVID death toll.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:data are available on-lineAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReferences 5 & 6 provide details for data https://www.worldometers.info/coronavirus/#countries.https://web.archive.org/web/20200630202020/https://www.cia.gov/library/publications/the-world-factbook/rankorder/2228rank.html ER -